Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WR | N.MMED.WS

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by shadowcatcheron Apr 04, 2012 8:09am
236 Views
Post# 19756990

RE: Insider Buying Update

RE: Insider Buying Update

More Insider buying 70000 shares on 4/2

As of 11:59pm ET April 3rd, 2012
Filing
Date		 Transaction
Date		 Insider Name Ownership
Type		 Securities Nature of transaction # or value acquired or disposed of Unit
Price
Apr 3/12 Apr 2/12 Gill, Derrick Edwin Direct Ownership Common Shares 10 - Acquisition in the public market 20,000
.770
Apr 3/12 Apr 2/12 Dawe, Wade K. Direct Ownership Common Shares 10 - Acquisition in the public market 50,000
.780
Apr 2/12 Mar 30/12 Nicholson, Jennifer Lynn Control or Direction Common Shares 10 - Acquisition in the public market 12,500
.788
Apr 2/12 Mar 30/12 Nicholson, Jennifer Lynn Control or Direction Common Shares 10 - Acquisition in the public market 12,500
.789
Apr 2/12 Mar 30/12 Hatfield, Dana Murray Direct Ownership Common Shares 10 - Acquisition in the public market 10,000
.800
Apr 2/12 Mar 30/12 Hatfield, Dana Murray Direct Ownership Common Shares 10 - Acquisition in the public market 20,000
.770
Apr 2/12 Mar 30/12 Dawe, Wade K. Direct Ownership Common Shares 10 - Acquisition in the public market 50,000
.780
Apr 2/12 Mar 30/12 Dawe, Wade K. Direct Ownership Common Shares 10 - Acquisition in the public market 100,000
.760
Mar 30/12 Mar 30/12 Kaiser, Marvin Indirect Ownership Common Shares 10 - Acquisition in the public market 10,000
.770
USD
Mar 30/12 Mar 30/12 Peat, David W. Direct Ownership Common Shares 10 - Acquisition in the public market 10,000
.770
USD
Sign

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities